SEC Form 4 · accession 0001209191-18-054162
Urovant Sciences Ltd. · UROV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Katkin
Officer — PEO;CEO-Urovant Sciences,Inc. · Director
Period of report
Oct 1, 2018
Accepted (ET)
Oct 3, 2018 · 9:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001740547
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $3.86 | Oct 1, 2018 | A | 200,250 | A | — | Sep 21, 2027 | Common Shares | 200,250 | 200,250 | D |
Explanation of responses
- F1The exercise price of this option is $3.86. In light of the performance-based vesting condition of this option grant, such option grant was not reportable under Section 16 until the performance-based vesting condition was satisfied. The performance-based vesting condition was satisfied on October 1, 2018.
- F2Subject to the achievement of the Issuer's performance measurement referred to in Footnote (1) herein on October 1, 2018, 25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.